|
ES2892925T3
(es)
|
2006-03-31 |
2022-02-07 |
Chugai Pharmaceutical Co Ltd |
Métodos para controlar la farmacocinética en sangre de anticuerpos
|
|
CN101874042B9
(zh)
|
2007-09-26 |
2019-01-01 |
中外制药株式会社 |
利用cdr的氨基酸取代来改变抗体等电点的方法
|
|
KR102057826B1
(ko)
|
2008-04-11 |
2019-12-20 |
추가이 세이야쿠 가부시키가이샤 |
복수 분자의 항원에 반복 결합하는 항원 결합 분자
|
|
TWI812066B
(zh)
|
2010-11-30 |
2023-08-11 |
日商中外製藥股份有限公司 |
具有鈣依存性的抗原結合能力之抗體
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
CN104540518A
(zh)
|
2012-04-27 |
2015-04-22 |
西托姆克斯治疗公司 |
结合表皮生长因子受体的可活化的抗体其使用方法
|
|
US20150203591A1
(en)
*
|
2012-08-02 |
2015-07-23 |
Regeneron Pharmaceuticals, Inc. |
Mutivalent antigen-binding proteins
|
|
EP3597747B1
(en)
|
2012-08-24 |
2023-03-15 |
Chugai Seiyaku Kabushiki Kaisha |
Mouse fcgammarii-specific fc antibody
|
|
TW202237660A
(zh)
|
2012-08-24 |
2022-10-01 |
日商中外製藥股份有限公司 |
FcγRIIb特異性Fc區域變異體
|
|
AU2014250434B2
(en)
|
2013-04-02 |
2019-08-08 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
|
WO2014193973A2
(en)
|
2013-05-28 |
2014-12-04 |
Dcb-Usa Llc |
Antibody locker for the inactivation of protein drug
|
|
CN105722859B
(zh)
*
|
2013-07-25 |
2021-05-07 |
西托姆克斯治疗公司 |
多特异性抗体、多特异性可活化抗体及其使用方法
|
|
CN104342453A
(zh)
*
|
2013-08-06 |
2015-02-11 |
深圳先进技术研究院 |
含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
|
|
WO2015066279A2
(en)
|
2013-10-30 |
2015-05-07 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
US9737623B2
(en)
|
2013-12-11 |
2017-08-22 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
|
UA129760C2
(uk)
|
2013-12-17 |
2025-07-30 |
Дженентек, Інк. |
Анти-cd3 антитіло та спосіб його застосування
|
|
CA2942281C
(en)
*
|
2014-03-26 |
2023-03-14 |
Siemens Healthcare Diagnostics Inc. |
Luminescent oxygen channeling immunoassay utilizing three antibodies and methods of production and use thereof
|
|
KR102366644B1
(ko)
*
|
2014-05-30 |
2022-02-22 |
상하이 헨리우스 바이오테크, 인크. |
항-표피 성장 인자 수용체 (egfr) 항체
|
|
US11820832B2
(en)
|
2014-07-25 |
2023-11-21 |
Memorial Sloan Kettering Cancer Center |
Bispecific HER2 and CD3 binding molecules
|
|
JP7020909B2
(ja)
|
2014-07-25 |
2022-02-16 |
シトムクス セラピューティクス，インコーポレイティド |
抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
|
|
US10519248B2
(en)
*
|
2014-07-25 |
2019-12-31 |
Memorial Sloan Kettering Cancer Center |
Bispecific HER2 and CD3 binding molecules
|
|
SI3221357T1
(sl)
|
2014-11-20 |
2020-09-30 |
F. Hoffmann-La Roche Ag |
Pogoste lahke verige in načini uporabe
|
|
RS61010B1
(sr)
|
2014-11-20 |
2020-11-30 |
Hoffmann La Roche |
Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
|
|
KR101860280B1
(ko)
|
2014-12-19 |
2018-05-21 |
추가이 세이야쿠 가부시키가이샤 |
항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
|
|
JP6744313B2
(ja)
*
|
2015-01-02 |
2020-08-26 |
ダイアックス コーポレーション |
血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
|
|
WO2016115274A1
(en)
*
|
2015-01-14 |
2016-07-21 |
Compass Therapeutics Llc |
Multispecific immunomodulatory antigen-binding constructs
|
|
CN114773470A
(zh)
|
2015-02-05 |
2022-07-22 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
|
|
CN108112254B
(zh)
*
|
2015-03-13 |
2022-01-28 |
西托姆克斯治疗公司 |
抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
|
|
CN107849133B
(zh)
*
|
2015-05-04 |
2022-08-23 |
西托姆克斯治疗公司 |
抗cd166抗体、可活化抗cd166抗体及其使用方法
|
|
BR112017023862A2
(pt)
*
|
2015-05-04 |
2018-07-17 |
Cytomx Therapeutics Inc |
anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
|
|
WO2016182064A1
(ja)
|
2015-05-13 |
2016-11-17 |
中外製薬株式会社 |
多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
|
|
US10202455B2
(en)
*
|
2015-05-20 |
2019-02-12 |
Immunwork Inc. |
Molecular constructs with targeting and effector moieties comprising an SCFV specific for ectodomain of transferrin-1 receptor and fingolimod
|
|
EA201792573A1
(ru)
|
2015-05-21 |
2018-04-30 |
Харпун Терапьютикс, Инк. |
Триспецифические связанные белки и способы их применения
|
|
EP3916018A1
(en)
|
2015-06-16 |
2021-12-01 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
CN116333144A
(zh)
|
2015-07-21 |
2023-06-27 |
武田药品工业株式会社 |
一种因子xiia的单克隆抗体抑制剂
|
|
US11466093B2
(en)
*
|
2015-07-27 |
2022-10-11 |
The General Hospital Corporation |
Antibody derivatives with conditionally enabled effector function
|
|
KR20240149974A
(ko)
|
2015-08-11 |
2024-10-15 |
고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 |
항체
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
EA039736B1
(ru)
*
|
2015-09-15 |
2022-03-04 |
Сайтомкс Терапьютикс, Инк. |
Анти-pdl1-антитела, активируемые анти-pdl1-антитела и способы их применения
|
|
CA2998961A1
(en)
|
2015-09-18 |
2017-03-23 |
Nestec S.A. |
Savoury concentrates with a flowable texture based on two starches
|
|
PE20240096A1
(es)
|
2015-10-02 |
2024-01-18 |
Hoffmann La Roche |
Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
|
|
KR102783230B1
(ko)
|
2015-11-09 |
2025-03-19 |
알.피.쉐러 테크놀러지즈 엘엘씨 |
항-cd22 항체-메이탄신 콘쥬게이트 및 그것의 사용 방법
|
|
ES2873846T5
(en)
|
2015-11-19 |
2025-06-23 |
Revitope Ltd |
Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
|
|
US10533157B1
(en)
|
2015-12-03 |
2020-01-14 |
Nantbio, Inc. |
Recombinant NK cells expressing co-stimulatory molecules
|
|
US11359009B2
(en)
|
2015-12-25 |
2022-06-14 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies and methods of use
|
|
SG11201805557SA
(en)
*
|
2016-01-08 |
2018-07-30 |
Bioalliance Cv |
Tetravalent anti-psgl-1 antibodies and uses thereof
|
|
EP3192810A1
(en)
*
|
2016-01-14 |
2017-07-19 |
Deutsches Krebsforschungszentrum |
Psma binding antibody and uses thereof
|
|
US12128102B2
(en)
|
2016-03-08 |
2024-10-29 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
CR20180453A
(es)
*
|
2016-03-22 |
2018-12-05 |
Hoffmann La Roche |
Moleculas biespecíficas de células t activadas por proteasas
|
|
HRP20230528T1
(hr)
*
|
2016-03-22 |
2023-08-04 |
F. Hoffmann - La Roche Ag |
Bispecifične molekule t stanica aktivirane proteazom
|
|
CN116987189A
(zh)
|
2016-05-20 |
2023-11-03 |
哈普恩治疗公司 |
单链可变片段cd3结合蛋白质
|
|
JP7101621B2
(ja)
|
2016-05-20 |
2022-07-15 |
ハープーン セラピューティクス，インク． |
単一ドメイン血清アルブミン結合タンパク質
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
US11617799B2
(en)
|
2016-06-27 |
2023-04-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
|
TWI693940B
(zh)
|
2016-08-05 |
2020-05-21 |
日商中外製藥股份有限公司 |
Ｉｌ-８相關疾病之治療用或預防用組成物
|
|
AU2017321625A1
(en)
*
|
2016-08-30 |
2019-04-04 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
CN106632681B
(zh)
|
2016-10-11 |
2017-11-14 |
北京东方百泰生物科技有限公司 |
抗egfr和抗cd3双特异抗体及其应用
|
|
CN110267982B
(zh)
*
|
2016-10-19 |
2024-02-23 |
斯克利普斯研究所 |
具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途
|
|
MA46770A
(fr)
*
|
2016-11-09 |
2019-09-18 |
Agenus Inc |
Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
|
|
WO2018093821A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
CN110198955A
(zh)
|
2016-11-23 |
2019-09-03 |
哈普恩治疗公司 |
前列腺特异性膜抗原结合蛋白质
|
|
EP3544629A4
(en)
|
2016-11-23 |
2020-06-17 |
Harpoon Therapeutics, Inc. |
PSMA TO BE TRISPECIFIC PROTEINS AND METHOD FOR USE THEREOF
|
|
EA201991353A1
(ru)
|
2016-12-09 |
2019-11-29 |
|
Двухвалентные антитела, маскированные спирализованными спиралями
|
|
EP3555620A1
(en)
|
2016-12-13 |
2019-10-23 |
H. Hoffnabb-La Roche Ag |
Method to determine the presence of a target antigen in a tumor sample
|
|
CN108264561B
(zh)
*
|
2016-12-30 |
2021-09-10 |
惠和生物技术(上海)有限公司 |
一种结合cd19、cd3和t细胞负共刺激分子的三功能分子及其应用
|
|
US11046768B2
(en)
|
2017-01-27 |
2021-06-29 |
Memorial Sloan Kettering Cancer Center |
Bispecific HER2 and CD3 binding molecules
|
|
SG11201907299XA
(en)
|
2017-02-08 |
2019-09-27 |
Dragonfly Therapeutics Inc |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
|
IL268755B2
(en)
|
2017-02-20 |
2025-12-01 |
Dragonfly Therapeutics Inc |
Proteins that bind her2, nkg2d, and cd16
|
|
CN120173123A
(zh)
*
|
2017-02-27 |
2025-06-20 |
蜻蜓疗法股份有限公司 |
靶向caix、ano1、间皮素、trop2、cea或紧密连接蛋白-18.2的多特异性结合蛋白
|
|
EP3589662A4
(en)
|
2017-02-28 |
2020-12-30 |
Harpoon Therapeutics, Inc. |
INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN
|
|
EP3601346A1
(en)
*
|
2017-03-29 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
WO2018177371A1
(en)
*
|
2017-03-29 |
2018-10-04 |
Taipei Medical University |
Antigen-specific t cells and uses thereof
|
|
AU2018250641B2
(en)
|
2017-04-11 |
2025-03-13 |
Inhibrx Biosciences, Inc. |
Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
|
|
CN108690138A
(zh)
*
|
2017-04-12 |
2018-10-23 |
鸿运华宁（杭州）生物医药有限公司 |
一种能与人cd19或cd20和人cd3结合的双特异性抗体及其应用
|
|
AU2018265856B2
(en)
|
2017-05-12 |
2023-04-27 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
|
WO2018209304A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
|
KR20200010430A
(ko)
*
|
2017-05-23 |
2020-01-30 |
드래곤플라이 쎄라퓨틱스, 인크. |
Nkg2d, cd16 및 종양-연관 항원에 결합하는 단백질
|
|
JP2020522486A
(ja)
|
2017-06-01 |
2020-07-30 |
サイトメックス セラピューティクス インコーポレイテッド |
活性化可能抗ｐｄｌ１抗体、およびその使用方法
|
|
EP3645050A4
(en)
*
|
2017-06-25 |
2021-08-11 |
Systimmune, Inc. |
Multi-specific antibodies and methods of making and using thereof
|
|
SG11201912865VA
(en)
*
|
2017-06-25 |
2020-01-30 |
Systimmune Inc |
Multi-specific antibodies and methods of making and using thereof
|
|
CN116948035A
(zh)
*
|
2017-06-25 |
2023-10-27 |
西雅图免疫公司 |
多特异性抗体及其制备和使用方法
|
|
TWI828625B
(zh)
*
|
2017-06-25 |
2024-01-11 |
美商西雅圖免疫公司 |
引導及導航控制蛋白質以及彼之製造及使用方法
|
|
JP2020530554A
(ja)
|
2017-07-20 |
2020-10-22 |
シートムエックス セラピューティクス，インコーポレイテッド |
活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用
|
|
CN111278461A
(zh)
|
2017-08-16 |
2020-06-12 |
百时美施贵宝公司 |
可前药化抗体、其前药以及使用和制备方法
|
|
IL302613B2
(en)
|
2017-09-08 |
2025-04-01 |
Maverick Therapeutics Inc |
Binding proteins are activated under limited conditions
|
|
HRP20241268T1
(hr)
|
2017-10-13 |
2024-12-06 |
Harpoon Therapeutics, Inc. |
Trispecifični proteini i postupci primjene
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
CA3287794A1
(en)
|
2017-10-14 |
2025-10-27 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
CA3082912A1
(en)
*
|
2017-12-11 |
2019-06-20 |
Triphase Accelerator U.S. Corporation |
Anti-cd22 antibody-maytansine conjugates, combinations, and methods of use thereof
|
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
|
DK3749346T3
(da)
|
2018-02-08 |
2024-09-09 |
Dragonfly Therapeutics Inc |
Antistof variable domænekombinationer rettet mod nkg2d-receptoren
|
|
JP7475275B2
(ja)
|
2018-02-08 |
2024-04-26 |
ジェネンテック， インコーポレイテッド |
二重特異性抗原結合分子及びその使用方法
|
|
EA202091887A1
(ru)
|
2018-02-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
|
|
WO2019164930A1
(en)
|
2018-02-20 |
2019-08-29 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
|
|
JP2021518603A
(ja)
|
2018-03-20 |
2021-08-02 |
シートムエックス セラピューティクス，インコーポレイテッド |
哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法
|
|
BR112020020604A2
(pt)
|
2018-04-11 |
2021-01-12 |
Inhibrx, Inc. |
Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados
|
|
TW202014436A
(zh)
|
2018-05-02 |
2020-04-16 |
美商Ｃｙｔｏｍｘ生物製藥公司 |
抗體、可活化之抗體、雙特異性抗體、及雙特異性可活化之抗體及使用彼之方法
|
|
EP3787691A1
(en)
|
2018-05-04 |
2021-03-10 |
Tagworks Pharmaceuticals B.V. |
Tetrazines for high click conjugation yield in vivo and high click release yield
|
|
KR20210020903A
(ko)
|
2018-05-14 |
2021-02-24 |
하푼 테라퓨틱스, 인크. |
면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티
|
|
CA3100005A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
AU2019271148B9
(en)
|
2018-05-14 |
2025-05-29 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
|
CA3101640A1
(en)
*
|
2018-06-04 |
2019-12-12 |
Trustees Of Tufts College |
Tumor microenvironment-activated drug-binder conjugates, and uses related thereto
|
|
IL279399B1
(en)
*
|
2018-06-14 |
2026-04-01 |
Bioatla Llc |
Multispecific antibody templates
|
|
WO2020023553A1
(en)
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
MA53333A
(fr)
*
|
2018-07-31 |
2021-11-03 |
Amgen Inc |
Formulations pharmaceutiques d'anticorps masqués
|
|
WO2020033630A1
(en)
|
2018-08-08 |
2020-02-13 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
US12378318B2
(en)
|
2018-08-08 |
2025-08-05 |
Dragonfly Therapeutics, Inc. |
Proteins binding NKG2D, CD16 and a tumor-associated antigen
|
|
WO2020061482A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Egfr binding proteins and methods of use
|
|
SG11202103022WA
(en)
|
2018-09-25 |
2021-04-29 |
Harpoon Therapeutics Inc |
Dll3 binding proteins and methods of use
|
|
MX2021003628A
(es)
*
|
2018-10-01 |
2021-05-27 |
Amgen Inc |
Metodos para reducir la agregacion de anticuerpos biespecificos.
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
WO2020076992A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
5t4 single domain antibodies and therapeutic compositions thereof
|
|
WO2020077257A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Pd-1 single domain antibodies and therapeutic compositions thereof
|
|
CA3115082A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
B7h3 single domain antibodies and therapeutic compositions thereof
|
|
EP3864045A2
(en)
|
2018-10-11 |
2021-08-18 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
CA3119390A1
(en)
|
2018-11-12 |
2020-05-22 |
Debiopharm International S.A. |
Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
|
|
WO2020181140A1
(en)
|
2019-03-05 |
2020-09-10 |
Maverick Therapeutics, Inc. |
Constrained conditionally activated binding proteins
|
|
US12516128B2
(en)
|
2019-05-14 |
2026-01-06 |
Harpoon Therapeutics, Inc. |
EpCAM binding proteins and methods of use
|
|
KR20220023988A
(ko)
|
2019-05-14 |
2022-03-03 |
웨어울프 세라퓨틱스, 인크. |
분리 모이어티 및 이의 사용 방법
|
|
IL322315A
(en)
|
2019-05-14 |
2025-09-01 |
Provention Bio Inc |
Methods and preparations for preventing type 1 diabetes
|
|
PE20220568A1
(es)
|
2019-05-21 |
2022-04-20 |
Novartis Ag |
Moleculas de union a cd19 y usos de las mismas
|
|
EP3984554A4
(en)
*
|
2019-06-11 |
2023-11-08 |
ONO Pharmaceutical Co., Ltd. |
IMMUNOSUPPRESSANT
|
|
US20220251206A1
(en)
|
2019-06-11 |
2022-08-11 |
Bristol-Myers Squibb Company |
Anti-ctla4 antibody prodruggable (probody) at a cdr position
|
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for increasing the speed and yield of the "click release" reaction
|
|
EP4382129A3
(en)
|
2019-06-17 |
2024-07-03 |
Tagworks Pharmaceuticals B.V. |
Compounds for fast and efficient click release
|
|
KR20210043475A
(ko)
|
2019-10-10 |
2021-04-21 |
주식회사 와이바이오로직스 |
다중 특이적 융합 단백질 및 이의 용도
|
|
CN114786730A
(zh)
|
2019-11-05 |
2022-07-22 |
再生元制药公司 |
N-端scFv多特异性结合分子
|
|
CN114502203B
(zh)
*
|
2019-11-06 |
2024-07-19 |
成都百利多特生物药业有限责任公司 |
制导和导航控制蛋白及其制备和使用方法
|
|
BR112022009110A2
(pt)
|
2019-11-14 |
2022-07-26 |
Werewolf Therapeutics Inc |
Polipeptídeos de citocina ativáveis e métodos de uso destes
|
|
WO2021097800A1
(en)
*
|
2019-11-22 |
2021-05-27 |
Abl Bio Inc. |
Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
|
|
JP2023504620A
(ja)
*
|
2019-12-06 |
2023-02-06 |
オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
抗ｏｘＭＩＦ／抗ＣＤ３二重特異性抗体構築物
|
|
WO2021119505A1
(en)
|
2019-12-13 |
2021-06-17 |
Genentech, Inc. |
Anti-ly6g6d antibodies and methods of use
|
|
CN115380047A
(zh)
|
2020-01-29 |
2022-11-22 |
印希比股份有限公司 |
Cd28单结构域抗体及其多价和多特异性构建体
|
|
EP4097135A4
(en)
*
|
2020-01-31 |
2024-07-03 |
Gensun Biopharma Inc. |
Bispecific t cell engagers
|
|
CA3170833A1
(en)
|
2020-02-21 |
2021-08-26 |
Harpoon Therapeutics, Inc. |
Flt3 binding proteins and methods of use
|
|
TWI874613B
(zh)
*
|
2020-03-17 |
2025-03-01 |
美商西雅圖免疫公司 |
微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
|
|
BR112022019841A2
(pt)
|
2020-04-09 |
2022-12-06 |
Cytomx Therapeutics Inc |
Composições contendo anticorpos ativáveis
|
|
MX2022013944A
(es)
|
2020-05-06 |
2022-11-30 |
Dragonfly Therapeutics Inc |
Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
|
|
AU2021287998B2
(en)
|
2020-06-11 |
2026-03-12 |
Benaroya Research Institute At Virginia Mason |
Methods and compositions for preventing type 1 diabetes
|
|
WO2022032006A2
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il2rb binding molecules and methods of use
|
|
AU2021322238A1
(en)
|
2020-08-05 |
2023-03-23 |
Synthekine, Inc. |
Compositions and methods related to IL27 receptor binding
|
|
US12122839B2
(en)
|
2020-08-05 |
2024-10-22 |
Synthekine, Inc. |
IFNGR binding synthetic cytokines and methods of use
|
|
JP7743500B2
(ja)
|
2020-08-05 |
2025-09-24 |
シンセカイン インコーポレイテッド |
Ｉｌ１０受容体結合性分子および使用方法
|
|
KR102846963B1
(ko)
|
2020-08-05 |
2025-08-18 |
신테카인, 인크. |
IL27Rα 결합 분자 및 사용 방법
|
|
BR112023001723A2
(pt)
|
2020-08-05 |
2023-05-02 |
Synthekine Inc |
Moléculas de ligação à gp130 e métodos de uso
|
|
US11859001B2
(en)
|
2020-08-05 |
2024-01-02 |
Synthekine, Inc. |
IL12RB1-Binding molecules and methods of use
|
|
WO2022031884A2
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il2rg binding molecules and methods of use
|
|
US12012457B1
(en)
|
2020-08-05 |
2024-06-18 |
Synthekine, Inc. |
IL23R binding molecules and methods of use
|
|
WO2022032045A1
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
IL10Rα/IL2Rγ SYNTHETIC CYTOKINES
|
|
JP7819178B2
(ja)
|
2020-08-05 |
2026-02-24 |
シンセカイン インコーポレイテッド |
ＩＬ１０Ｒｂ結合分子および使用方法
|
|
WO2022032037A1
(en)
*
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il23 receptor synthetic cytokines and methods of use
|
|
US12291572B2
(en)
|
2020-08-05 |
2025-05-06 |
Synthekine, Inc. |
IL12 receptor synthetic cytokines and methods of use
|
|
KR20230061394A
(ko)
|
2020-08-05 |
2023-05-08 |
신테카인, 인크. |
IL10Ra 결합 분자 및 사용 방법
|
|
US12018085B2
(en)
|
2020-08-05 |
2024-06-25 |
Synthekine, Inc. |
Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases
|
|
TW202237653A
(zh)
*
|
2020-12-09 |
2022-10-01 |
美商詹努克斯治療有限公司 |
與經腫瘤活化之靶定trop2及效應細胞抗原之抗體相關之組合物及方法
|
|
WO2022170619A1
(en)
*
|
2021-02-11 |
2022-08-18 |
Adagene Pte. Ltd. |
Anti-cd3 antibodies and methods of use thereof
|
|
JP2024508894A
(ja)
|
2021-03-03 |
2024-02-28 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
|
|
WO2022216992A1
(en)
*
|
2021-04-08 |
2022-10-13 |
Board Of Regents, The University Of Texas System |
Methods for activation and expansion of natural killer cells and combinations with bispecific antibodies
|
|
US12291575B2
(en)
|
2021-05-14 |
2025-05-06 |
Genentech, Inc. |
Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
US12565529B2
(en)
|
2021-05-24 |
2026-03-03 |
Provention Bio, Inc. |
Methods for treating type 1 diabetes
|
|
AU2022367525A1
(en)
|
2021-10-15 |
2024-05-02 |
Amgen Inc. |
Activatable polypeptide complex
|
|
WO2023064955A1
(en)
|
2021-10-15 |
2023-04-20 |
Cytomx Therapeutics, Inc. |
Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
|
|
JP2024539650A
(ja)
|
2021-10-15 |
2024-10-29 |
シートムエックス セラピューティクス，インコーポレイテッド |
活性化可能なポリペプチド複合体
|
|
EP4434548A1
(en)
|
2021-11-15 |
2024-09-25 |
Systimmune, Inc. |
Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
|
|
US20250136689A1
(en)
*
|
2022-02-04 |
2025-05-01 |
Duke University |
Compositions for and methods of treating hematological cancers
|
|
AU2023217735A1
(en)
*
|
2022-02-11 |
2024-07-25 |
Interius Biotherapeutics, Inc. |
Fusogenic rhabdovirus glycoproteins and uses thereof
|
|
CN114316062B
(zh)
*
|
2022-03-02 |
2022-06-07 |
珠海臻谱基因科技有限公司北京分公司 |
靶向HIV gp120蛋白和人CD3分子的多特异性抗体及其应用
|
|
CA3247048A1
(en)
|
2022-04-13 |
2023-10-19 |
Genentech, Inc. |
PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE
|
|
EP4619427A1
(en)
*
|
2022-11-15 |
2025-09-24 |
F. Hoffmann-La Roche AG |
Recombinant binding proteins with activatable effector domain
|
|
WO2025036848A1
(en)
|
2023-08-11 |
2025-02-20 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Anti-muc16 antibodies and uses thereof
|
|
WO2025038668A1
(en)
|
2023-08-14 |
2025-02-20 |
Voro Therapeutics, Inc. |
Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
|
|
CN121712801A
(zh)
|
2023-08-14 |
2026-03-20 |
莫佛塞斯有限责任公司 |
包含空间位阻部分的CyCAT半体分子
|
|
AR134514A1
(es)
|
2023-12-01 |
2026-01-21 |
Gilead Sciences Inc |
Proteína de fusión anti-fap-ligera y uso de esta
|
|
WO2025189116A1
(en)
*
|
2024-03-08 |
2025-09-12 |
Synthetic Design Lab, Inc. |
Multivalent multispecific constructs for targeted payload delivery
|
|
US20250297006A1
(en)
*
|
2024-03-20 |
2025-09-25 |
Regeneron Pharmaceuticals, Inc. |
Masked Multispecific Antigen-Binding Molecules with Cleavable Linkers
|
|
WO2025235515A1
(en)
|
2024-05-07 |
2025-11-13 |
Cytomx Therapeutics, Inc. |
Activatable polypeptide complex formulations
|
|
WO2025240659A2
(en)
|
2024-05-14 |
2025-11-20 |
Cytomx Therapeutics, Inc. |
Activatable constructs, compositions and methods
|
|
WO2025237931A1
(en)
*
|
2024-05-15 |
2025-11-20 |
F. Hoffmann-La Roche Ag |
Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains
|
|
US20260056209A1
(en)
|
2024-06-14 |
2026-02-26 |
Gilead Sciences, Inc. |
Anti-ccr8 antibodies and uses thereof
|
|
WO2026024841A1
(en)
*
|
2024-07-24 |
2026-01-29 |
Astellas Us Llc |
Bispecific antibodies that bind cd3 and muc1 and methods of use thereof
|